About the Hemostasis and Thrombosis Program
As one of 134 federally funded hemophilia treatment programs across the country, Texas Children’s Hemostasis and Thrombosis Program is part of a national network designed to provide state-of-the-art care to children with congenital bleeding and thrombotic disorders.
We provide comprehensive diagnostic and treatment programs, social services, and psychological, dental and orthopedic specialty support for the long term evaluation and treatment of children with many conditions, including:
- Heavy menstrual bleeding
- Platelet disorders
- Von Willebrand disease
- Other bleeding or clotting disorders
Our dedicated multidisciplinary team follows patients both in the clinic and in the hospital setting. Our Anticoagulation Program, staffed with pediatric hematologists and hematology nurses, helps patients monitor their often complicated drug therapy both in and out of the hospital.
Our team works closely with other leading experts throughout Texas Children’s Hospital to optimize care of patients with bleeding and clotting disorders. These collaborative efforts include advanced interventional technologies to treat complicated cases of thrombosis and life-threatening bleeding.
Young Women’s Bleeding Disorder Clinic. In collaboration with Pediatric and Adolescent Gynecology at Texas Children’s Hospital, we coordinate a Young Women’s Bleeding Disorder Clinic to follow and treat patients with heavy menstrual bleeding and bleeding disorders in a comprehensive and coordinated manner. Our clinic provides “one-stop” care for gynecologic, hematologic and psychosocial issues for teenagers. Learn more.
Thrombosis Clinic. The Thrombosis Clinic treats patients with thrombosis, stroke, and thrombophilia.
Hemophilia Clinic. The Hemophilia Clinic treats patients with congenital bleeding disorders, such as Von Willebrand disease.
Renowned for our research and therapies for blood disorders, we conduct state-of-the-art clinical and scientific research aimed at increasing our understanding of bleeding and clotting disorders and developing new, more effective therapies for children who suffer from them. Our clinical research is focused on novel agents that increase safety, convenience and effectiveness of therapy for patients.